Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intra-Cellular Therapies (ITCI) reports stellar Q4 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q4 2022, driven by robust sales growth of CAPLYTA and a focus on expanding clinical programs.
While facing challenges in managing expenses and navigating market dynamics, the company is well-positioned to capitalize on opportunities in new indications and patient education initiatives.
ITCI's strategic investments in innovation and market expansion underscore its commitment to long-term growth and addressing mental health needs through novel treatment options.

Intra-Cellular Therapies reports robust Q1 performance and growth prospects

ITCI's strong Q1 performance driven by CAPLYTA and promising results from lumateperone studies position the company well for future growth.
Addressing unmet needs in MDD and bipolar depression, along with ongoing pipeline progress, showcases ITCI's commitment to innovation in neuropsychiatric treatments.
While facing challenges in market share data and increasing expenses, opportunities lie in expanding sales force, new indications for pipeline programs, and driving awareness for CAPLYTA.

Intra-Cellular Therapies (ITCI) reports strong Q2 performance and expands treatment portfolio

Intra-Cellular Therapies (ITCI) demonstrated robust performance in Q2, driven by strong revenue growth and promising developments in its product portfolio.
The company's financial strength, innovative pipeline, and focus on addressing unmet medical needs position it well for future growth and success.
While facing challenges in revenue guidance clarity and resource allocation, ITCI has opportunities to expand its market reach and improve patient outcomes.
By leveraging its strengths and addressing challenges effectively, Intra-Cellular Therapies (ITCI) can capitalize on opportunities to drive continued growth and innovation.

Intra-Cellular Therapies (ITCI) excels in Q3, eyes market expansion

Intra-Cellular Therapies (ITCI) showcased strong financial performance and growth prospects in Q3 2023, driven by CAPLYTA's success and pipeline advancements.
While the company faces challenges in sustaining growth and navigating regulatory complexities, opportunities in market expansion and innovation are key for future success.
ITCI's focus on expanding indications, clinical advancements, and financial strength position it well for continued growth and leadership in the pharmaceutical industry.

Intra-Cellular Therapies (ITCI) reports robust growth and strategic expansion

Intra-Cellular Therapies (ITCI) delivered a strong performance in 2023, with robust revenue growth and strategic plans for pipeline advancement and market expansion.
The company faces challenges in managing expenses, optimizing market penetration, and navigating competitive dynamics, but opportunities in sales growth and innovation are evident.
Overall, Intra-Cellular Therapies (ITCI) is well-positioned for continued success, with a focus on driving growth through product differentiation and market positioning.

Intra-Cellular Therapies (ITCI) reports strong Q1 earnings and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong Q1 2024 earnings driven by robust CAPLYTA sales and positive results in MDD studies, positioning the company for future growth.
With a solid financial position, a broad label strategy, and a focus on pipeline expansion, ITCI is well-equipped to capitalize on market opportunities and drive long-term success.
While facing near-term uncertainties and challenges, ITCI's strategic initiatives and ongoing studies present significant opportunities for expanding its market reach and revenue potential.
Overall, ITCI's commitment to developing innovative medicines and its market acceptance indicate a promising outlook for sustained growth and value creation.

Intra-Cellular Therapies (ITCI) reports robust Q3 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q3 2024, driven by CAPLYTA's sales growth and strategic investments in R&D.
The company's focus on innovation, with new program initiations and pipeline advancements, positions it well for future growth and market expansion.
While facing challenges in a competitive market and cost management, ITCI's solid financial position and promising pipeline offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

SAN DIEGO--(BUSINESS WIRE)-- #Antibodies--Proteintech Genomics launches commercially available solution for the detection of intracellular proteins for single-cell RNAseq experiments.

Proteintech Genomics Launches First Commercially Available Solution for the Detection of Intracellular Proteins for Single-Cell RNAseq Experiments

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Chief Commercial Officer Larry Hineline – Chief Financial Officer Suresh Durgam – Chief Medical Officer Conference Call Participants Tanmay Patwardhan – J.P. Morgan Andrew Tsai – Jefferies Charles Duncan – Cantor Fitzgerald Umer Raffat – Evercore Michael Riad – Morgan Stanley Marc Goodman – Leerink Ami Fadia – Needham & Company Graig Suvannavejh – Mizuho Securities Jason Gerberry – Bank of America Corinne Jenkins – Goldman Sachs Operator Thank you for standing by, and welcome to the Intra-Cellular Therapies 3Q 2023 Earnings Conference Call.

Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript

Q3 2023 total revenues increased to $126.2 million , compared to $71.9 million in the same period in 2022

Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 2, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2023.

Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:15 p.m. ET.

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the 2023 Psych Congress held September 6 - 10, 2023 in Nashville.

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 at 12:55 p.m. ET.

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings report showed substantial revenue growth driven by Caplyta's net product sales, although the company still recorded a net loss. The company's growth initiatives include exploring the potential of lumateperone in Major Depressive Disorder, developing new formulations, and expanding their pipeline with new programs.

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth.

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET.

Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Executive Officer Mark Neumann - Executive Vice President, Chief Commercial Officer Larry Hineline - Senior Vice President of Finance and Chief Financial Officer Suresh Durgam - Executive Vice President, Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Marc Goodman - SVB Leerink Charles Duncan - Cantor Fitzgerald Jason Gerberry - Bank of America Michael Riad - Morgan Stanley Sumant Kulkarni - Canaccord Genuity Corinne Jenkins - Goldman Sachs Ash Verma - UBS David Amsellem - Piper Sandler Umer Raffat - Evercore ISI Ami Fadia - Needham & Company, LLC Graig Suvannavejh - Mizuho Securities Operator Good morning. And welcome to Intra-Cellular Therapies Second Quarter Financial Results Conference Call.

Intra-Cellular Therapies, Inc. (ITCI) Q2 2023 Earnings Call Transcript

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for the same period in 2022, representing a 100% increase CAPLYTA's strong prescription uptake continues: Q2 2023 CAPLYTA total prescriptions increased 96%, versus the same period in 2022 and 13% sequentially versus Q1 2023 2023 CAPLYTA net product sales guidance raised to $445 - $465 million NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Our continued commercial execution resulted in another quarter of solid growth for CAPLYTA.

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, August 3, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2023.

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

Growth stock Intra-Cellular Therapies is finding support at its 21-day moving line with a strong record of impressive sales growth.

Drug Stock Poised For Growth With Record Sales, Strong Outlook

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 2:00 p.m. PT.

Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 30 - June 2, 2023.

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schizophrenia and bipolar depression. Caplyta faces exclusivity expiration in December 2024, compelling Intra-Cellular to rely on Orange Book patents and promising pipeline candidates.

Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Juan Sanchez – Vice President-Corporate Communications and Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Chief Commercial Officer Larry Hineline – Chief Financial Officer Suresh Durgam – Chief Medical Officer Conference Call Participants Vardhman Chhajed – JPMorgan Leonid Timashev – RBC Capital Markets Andrew Tsai – Jefferies Charles Duncan – Cantor Fitzgerald Jeff Hung – Morgan Stanley Sumant Kulkarni – Canaccord Genuity Marc Goodman – SVB Leerink Umer Raffat – Evercore ISI Jason Gerberry – Bank of America Ash Verma – UBS David Amsellem – Piper Sandler Corinne Jenkins – Goldman Sachs Graig Suvannavejh – Mizuho Securities Operator Good morning and welcome to Intra-Cellular Therapies First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Intra-Cellular Therapies, Inc. (ITCI) Q1 2023 Earnings Call Transcript

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA total prescriptions increased 159%, versus the same period in 2022 and 16% sequentially versus Q4 2022 Reiterating CAPLYTA 2023 net product sales guidance of $430 to $455 million Announced robust positive results from Study 403 in patients with mixed features in major depressive disorder (MDD) and mixed features in bipolar depression NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are pleased with the progress we have made in the first quarter and we are confident in the continued growth of CAPLYTA,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at two upcoming investor conferences:

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2023.

News for Intra-Cellular Therapies Stock (ITCI)